Mylan Laboratories Limitted

In-house

수2816-1ND(2)

4-[bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid

Deferasirox

Deferasiroxum

Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.

201530-41-8

If you need more information, please contact us.

Hubei Biocause Heilen Pharmaceutical

Solara Active Pharma Sciences Limited

In-house

20120330-145-I-36-01(5) / 20130208-145-I-184-04(16)

(+)-(S)-p-isobutylhydratropic acid

(2S)-2-(4-isobutylphenyl)propanoic acid

(S)-α-methyl-4-(2-methylpropyl)benzeneacetic acid

d-ibuproten

Dexibuprofen, S(+)-ibuprofen, is a non-steroidal anti-inflammatory drug (NSAID). It is a pharmacologically effective enantiomer of racemic ibuprofen that differs in physicochemical properties. It is proposed to be more pharmacologically active and tolerable with a better safety profile than ibuprofen due to higher concentration of active S enantiomer. Dexibuprofen has a slower dissolution rate in the simulated gastric and enteric juices compared with the racemic ibuprofen and displays improved oral bioavilability. For Metabolism, Enzymes, Carriers, Transporters Sections, refer to Ibuprofen.

51146-56-6

If you need more information, please contact us.

Hubei Biocause Heilen Pharmaceutical

KP

20120406-145-I-37-02(3)

(2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid

(+)-(S)-p-isobutylhydratropic acid
(2S)-2-(4-isobutylphenyl)propanoic acid
(S)-α-methyl-4-(2-methylpropyl)benzeneacetic acid
d-ibuproten
Dexibuprofeno

Dexibuprofen, S(+)-ibuprofen, is a non-steroidal anti-inflammatory drug (NSAID). It is a pharmacologically effective enantiomer of racemic ibuprofen that differs in physicochemical properties. It is proposed to be more pharmacologically active and tolerable with a better safety profile than ibuprofen due to higher concentration of active S enantiomer. Dexibuprofen has a slower dissolution rate in the simulated gastric and enteric juices compared with the racemic ibuprofen and displays improved oral bioavilability 4. For Metabolism, Enzymes, Carriers, Transporters Sections, refer to Ibuprofen.

51146-56-6

If you need more information, please contact us.

Mylan Laboratories Limited (Unit-7)

In-house

20171024-209-J-174

2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazol

Dexlansoprazole is a new generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of Lansoprazole, which is composed of a racemic mixture of the R- and S-enantiomers. Compared to the older generation of PPIs (which includes Pantoprazole, Omeprazole, and Lansoprazole), dexlansoprazole MR has a unique pharmacokinetic profile due to its delayed-release and dual-delivery release system. The active ingredient is released in two phases at different pH values and at different time points, resulting in two peak concentrations in the blood; 25% of the dose is released at pH 5.5 in the proximal duodenum, while the remaining 75% is released at pH 6.75 in the distal small intestine. As a result, dexlansoprazole has a peak concentration within 1-2 hours after dosing and another within 4-5 hours. Dexlansoprazole's unique pharmacokinetics addresses limitations of the older generation PPIs including short plasma half-life, break-through symptoms, and need for meal-associated dosing. These characteristics make dexlansoprazole a good option for people who struggle with adherence and strict dosage timing before meals.

138530-94-6

If you need more information, please contact us.

FSP Galena

EP

수289-5-ND

calcium 2,5-dihydroxybenzenesulfonate

Calcium 2,5-Dihydroxybenzenesulfonate Hydrate

2,5-Dihydroxybenzenesulfonic Acid Calcium Salt Hydrate

Calcium dobesilate is a vasoprotective. It is the calcium salt of dobesilic acid. It is a synthetic molecule with the ability to reduce capillary permeability in the body. In Italy the drug is sold by the pharmaceutical company OM Pharma under the trade name of Doxium in capsules containing 500 mg of active ingredient.

20123-80-2

If you need more information, please contact us.

Ami Lifesciences Private Limited.

In-house

20181029-209-J-98

Doxophylline

Doxofylline is a methylxanthine derivative with the presence of a dioxolane group in position 7. As a drug used in the treatment of asthma, doxofylline has shown similar efficacy to theophylline but with significantly fewer side effects in animal and human studies. In contrast with other xanthine derivatives, doxofylline does not significantly bind to adenosine alpha-1 or alpha-2 receptors and lacks stimulating effects. Decreased affinity for adenosine receptors may account for the better safety profile of doxofylline compared to theophylline . Unlike theophylline, doxofylline does not affect calcium influx and does not antagonize the actions of calcium channel blockers which could explain reduced cardiac adverse reactions associated with the drug. The anti-asthmatic effects of doxophylline are mediated by other mechanisms, primarily through inhibiting the activities of the phosphodiesterase (PDE) enzyme.

69975-86-6

If you need more information, please contact us.